Caring for women
for nearly 50 years
At Theramex we provide therapies that help women to live better lives.
We have a portfolio of medicines covering contraception, fertility, menopause and osteoporosis, and we continue to complement our range with new and innovative treatments.
The Theramex brand is established
Merck acquires Theramex
Teva Pharmaceuticals acquires Theramex and introduces the Teva Women’s Health brand.
Teva Women’s Health is sold to CVC Capital Partners, creating an international pharmaceutical company dedicated to Women’s Health.
The new Theramex is born.
Our leadership team
Our industry-leading global team includes more than 350 talented, experienced, multi-disciplinary professionals, many of whom have dedicated their careers to Women’s Health.
Our leadership team, headed by Anish Mehta, is based at our Central London HQ.
Anish has over 20 years’ pharmaceuticals experience with large multinational companies such as Abbott Laboratories, McKinsey, Baxter, Watson/Actavis and Allergan. Trained as a Biomedical and Chemical Engineer, Anish started his career in engineering and manufacturing operations before moving to the commercial side of the business, where he held leadership roles across strategy, marketing and corporate development and general management.
Anish has spent the past 10 years in Europe both managing businesses and leading significant transformational M&A deals, including the market shaping $40B divestiture of the Actavis Global Generics business to Teva. After leaving Allergan, where he was the Head of International Corporate Development, Anish was appointed as Chief Executive Officer of Theramex.
Ciarán has over 25 years’ of leadership, finance and accounting experience, and has worked across three continents and a range of industries including Banking, Insurance and Travel and Telecommunications at major corporations such as GE, TUI and Bank of Ireland.
Ciarán is a Chartered Accountant and has held positions as CEO and CFO in businesses in Ireland, UK, France and South Korea.
EVP: Corporate Development
Susanna has over 15 years’ experience in global senior leadership roles in the Pharmaceutical industry. She has a rich background in developing and implementing geographic expansion plans and developing sustainable pipelines by transacting on multi-geography licensing, development, and M&A deals in the speciality, generic and clinical stage space.
She started her business development career in Barcelona, Spain, working with speciality R&D houses, and was part of the Mylan due diligence team that lead to the acquisition of the Merck Generics business.
EVP: Human Resources
Anjuna has over 20 years’ experience in pharmaceuticals ranging from generics to biotechnology in organisations such as Ranbaxy, Chiron/Novartis, Watson/Actavis, Forest and Allergan where she has had roles of increasing responsibility and leadership in HR and Integration.
A graduate in European Studies, Anjuna trained as a Management Accountant, and after her MBA she moved swiftly into Human Resources. Over the last eight years, Anjuna has led integration and transformational change projects, partnering closely with the business. In her last role at Allergan before joining Theramex, Anjuna was the Executive Director for the International multi-functional site in Marlow and the business partner for Southern and Western Europe ($1.1b).
EVP: Commercial Operations
Tim has over 25 years’ experience in the Pharmaceutical industry. Originally trained as a Biologist, he has gone on to hold multiple positions in commercial operations within major healthcare companies. Tim has led commercial teams across Europe, the Middle East, Africa and Asia.
He has built a deep expertise leading organisations through major transformation and growth programmes, working effectively across different businesses and cultures. After leaving Merck, where he was Head of the European Pharmaceutical Business, Tim was appointed as EVP Head of Global Commercial Operations of Theramex.
EVP: Global Operations
Gilad has spent 12 years in the Pharmaceutical industry leading large-scale performance transformations across public and privately owned pharmaco’s. Most of his work has been in the context of mergers, acquisitions and complex carveouts backed by Private Equity houses. Experienced across all business functions, his focus has been driving impact in operations, supply chain and quality.
Prior to joining Theramex’s leadership team, Gilad was a Partner in McKinsey and Company’s London office where he was co-leader of the EMEA Private Equity and Pharma practices, and led the PE Portfolio service line. Trained in bioinformatics, Gilad also served the public sector for 10+ years in operational leadership roles.
Matthew has over 20 years’ legal pharmaceuticals experience gained working in both private practice and in-house environments. Matthew began his legal career as a patent litigator at Bristows, subsequently moving to the intellectual property team at Baker & McKenzie. He then joined BTG as senior counsel before taking up a post at Sun (then Ranbaxy) as its European Legal Director.
Most recently he was General Counsel at Circassia where he led the legal and compliance functions and was responsible for the legal aspects of the acquisitions of Prosonix and Aerocrine and for the company’s strategic collaboration with AstraZeneca. Matthew was appointed General Counsel of Theramex in June 2018.
EVP: Global Fertility
Gavin has 25 years’ experience in the Pharma and Biotech industry in Commercial and Senior Management roles. In the majority of those roles, and for the past 18 years, he has specialised in building and leading fertility businesses.
As a graduate of Psychology and Health, he started his career in the Pharmaceutical industry with Serono (latterly Merck Serono) and then joined Ferring to lead their fertility business. He then joined Finox, a small start-up biotech, and managed the development, registration, and commercial launch of the first biosimilar rFSH to market worldwide. He built the company into a globally active commercial and manufacturing enterprise, and after three years led the sale of the company to Gedeon Richter for 190MCHF. Gavin joined Theramex in November 2018 to lead the Fertility Business for the company.